TFRC and Autoimmunity: Development of secondary autoimmunity following alemtuzumab therapy likely reflects a coincidence of several unfortunate factors including a skewed Tfh : Tfr cell ratio, homeostatic proliferation of T cells, a delayed Treg response and exhausted T cells.